Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | PDE6D | O43924 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979238 | 0.97 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1740204 | 0.97 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1739611 | 0.96 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2684323 | 0.96 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1741831 | 0.96 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3885922 | 0.92 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3884325 | 0.91 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL6789988 | 0.87 | HMGCR (0.59) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3971716 | 0.87 | HMGCR (0.58) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16401135 | 0.84 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483248-B1 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR ZRT (HU) | 2016-07-20 | — | — | EP | disclosed |
| US-9321733-B2 | Crystalline pharmaceutically active ingredients | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2016-04-26 | — | — | US | disclosed |
| US-9023838-B2 | Crystalline form I rosuvastatin zinc salt | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE (HU) | 2015-05-05 | — | — | US | disclosed |
| US-20130296353-A1 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | EGIS Gyogyszergyar Nyilvanosan Mukodo Reszvenytar- sasag (HU) | 2013-11-07 | — | — | US | disclosed |
| EP-2640710-A2 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2013-09-25 | — | — | EP | disclosed |
| US-8507513-B2 | Process for the preparation of rosuvastatin salts | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2013-08-13 | — | — | US | disclosed |
| US-20120178729-A1 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE (HU) | 2012-07-12 | — | — | US | disclosed |
| WO-2012066365-A2 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2012-05-24 | — | — | WO | disclosed |
| US-20120116082-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2012-05-10 | — | — | US | disclosed |
| EP-2389365-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | Egis Gyógyszergyár Nyilvánosan Müködö (HU) | 2011-11-30 | — | — | EP | disclosed |
| US-8040819-B2 | Discovery and identification of upstream device characteristics for self-configuration of customer premises equipment | CISCO TECHNOLOGY, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010082072-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | EGIS GYÓGYSZERGYÁR (HU) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116082-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS | TERT, SLC30A6, HMGCR | HMGCR 3/4885ALDH1A1 2602/4885CYP3A4 427/4885 |
| US-20120178729-A1 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT | SLC39A11, PCSK9, SLC39A3 | HMGCR 7/4885ALDH1A1 2875/4885CYP3A4 1043/4885 |
| US-20130296353-A1 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS | PCSK9, SLC39A11, SLC10A1 | HMGCR 5/4885ALDH1A1 2460/4885CYP3A4 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.